Related Experiment Video
Updated: Oct 4, 2025

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Novel antifungal agents in clinical trials
Samantha E Jacobs1, Panagiotis Zagaliotis2, Thomas J Walsh2,3
1Division of Infectious Diseases, Icahn School of Medicine, New York, NY, 10029-5674, USA.
Abstract:
Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics. This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim. We discuss three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties.
Related Concept Videos
Clinical Trials: Overview
Antimicrobial Effectiveness
Clinical Trials
There are four phases in a clinical trial. A phase one...
Fungal Group Zygomycota
Fungal Phylum Microsporidia
Fungal Phylum Basidiomycota

